Mitsubishi Ufj Kokusai Asset Management Co., Ltd. Design Therapeutics, Inc. Transaction History

Mitsubishi Ufj Kokusai Asset Management Co., Ltd.

$92.2 Billion
Q3 2024

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q1 2023 May 08, 2023	BUY	$5.5 - $9.77 $14,393 - $25,568	2,617 Added 15.68%	19,306 $111,000
Q4 2022 Feb 07, 2023	BUY	$7.86 - $17.2 $131,175 - $287,050	16,689 New	16,689 $171,000

Others Institutions Holding DSGN

# of Institutions

102

Shares Held

31M

Call Options Held

2.3K

Put Options Held

16.5K

Sr One Capital Management, LP

6.53M
Shares

$40.5 Million
11.88% of portfolio
Logos Global Management LP San Francisco, CA

4.22M
Shares

$26.2 Million
3.0% of portfolio
Black Rock Inc. New York, NY

2.3M
Shares

$14.3 Million
0.0% of portfolio
Frazier Life Sciences Management, L.P. Menlo Park, CA

1.89M
Shares

$11.8 Million
0.55% of portfolio
Baker Bros. Advisors LP New York, NY

1.74M
Shares

$10.8 Million
0.1% of portfolio

View Full List

About Design Therapeutics, Inc.

Ticker DSGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,807,900
Market Cap $347M
Description
Design Therapeutics, Inc. a preclinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of genetic diseases caused by nucleotide repeat expansions. The company's portfolio of products comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ syste...

More about DSGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Mitsubishi Ufj Kokusai Asset Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Mitsubishi Ufj Kokusai Asset Management Co., Ltd. with notifications on news.

Account